newsfilter
← Latest News
GlobeNewswire·

Innoviva to Acquire Entasis Therapeutics

Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cash Price per share in cash represents a 50% premium to Entasis' closing price of $1.47 per share on January 31, 2022, the last date before Innoviva's